The FDA on September 19, 2025, approved KEYTRUDA QLEX® (Pembrolizumab and Berahyaluronidase alfa-pmph) (Keytruda Qlex, Merck) for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab (Keytruda, Merck). See the prescribing information for the specific indications.
Bottom Ad
Advertisement
Subscribe
